Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Rare Disease Diagnostics Market?

The market size for diagnosing rare diseases has seen robust growth in the past few years. Expected to rise from $35.23 billion in 2024 to $38.22 billion in 2025, it will achieve a compound annual growth rate (CAGR) of 8.5%. The historic growth can be linked to the surge in demand for cloud-based diagnostics, a higher emphasis on enhancing efficiency, growing incidence of neurological disease, an upswing in immunological disorders, and increased healthcare expenditure.

What Growth Rate Is Forecasted for the Rare Disease Diagnostics Market by 2029?

The market for diagnosing rare diseases is anticipated to experience significant expansion in the coming years, ballooning to a value of $56.23 billion by 2029, with a compound annual growth rate (CAGR) of 10.1%. The progression during the predicted timeframe can be ascribed to several elements including a rising number of rare disease occurrences, governmental support, the growth of hospitals and diagnostic laboratories, the surge in hematology diseases, and the expanding health care infrastructure. Foreseen trends during this period consist of breakthroughs in genetic testing methods, the launch of whole-genome and next-generation sequencing (NGS), substantial financial inputs, and strategic partnerships geared towards research exploration.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

Which Key Companies Are Shaping the Future of the Rare Disease Diagnostics Market?

Major companies operating in the rare disease diagnostics market include Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Astellas Pharma Inc., Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio-Rad Laboratories Inc., Qiagen NV, BioMarin Pharmaceutical Inc., OPKO Health Inc., Sarepta Therapeutics Inc., Natera Inc., Invitae Corporation, Ultragenyx Pharmaceutical Inc., Travere Therapeutics Inc., BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., Agios Pharmaceuticals Inc., Orphazyme A/S, RareCyte Inc.

Which Factors Are Driving Demand in the Rare Disease Diagnostics Industry?

The rare disease diagnostics market is anticipated to expand due to the rising occurrence of rare ailments. These diseases, which are less prevalent compared to other standard illnesses, affect a small fraction of the population. Efficient treatment is enhanced by rare disease diagnostics as they assist in comprehensively managing the disease, pinpointing potential treatment options, and preventing unnecessary treatments that could result in severe side effects. For example, Health Match, a digital health organization based in Australia, reported in November 2022 that there are roughly 150 uncommon kidney diseases. These illnesses are highly prevalent worldwide, with a rate of 60–80 cases per 100,000 individuals in the United States and Europe. As such, the escalating incidence of rare diseases is fuelling the growth of the rare disease diagnostics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

How Is the Rare Disease Diagnostics Market Segmented by Several Divisions?

The rare disease diagnostics market covered in this report is segmented –

1) By Test Type: Genetic Test, General Lab Test, Imaging Test

2) By Technology: Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays

3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample, Buccal Swab Sample, Blood, Saliva

4) By Disease Type: Gastroenterology Disease, Endocrine And Metabolism Disorders Disease, Hematology And Oncology Disease, Dermatology Disease, Cardiovascular Disorders, Neurology Disease

5) By End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories

Subsegments:

1) By Genetic Test: Whole Genome Sequencing, Targeted Gene Panels, Exome Sequencing, Carrier Testing

2) By General Lab Test: Blood Tests, Biochemical Assays, Urine Tests, Cytogenetic Tests

3) By Imaging Test: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scans, Ultrasound, X-Rays

What are the Emerging Market Trends Driving the Growth of the Rare Disease Diagnostics Industry?

Innovations in technology are becoming a prominent trend within the rare disease diagnostics market. Major players in the market are adopting these advancements to maintain their market position. For example, Centogene GmbH, a German-based rare disease company, introduced CentoGenome, a whole genome sequencing solution for diagnosing rare and neurodegenerative illnesses, in April 2023. CentoGenome is an improved next-generation sequencing (NGS)-based test that provides whole genome sequencing (WGS) examinations for both rare and neurodegenerative conditions. It can detect almost all disease-triggering variants in one go. Its sensitivity in detecting Copy Number Variations (CNVs) associated with Spinal Muscular Atrophy (SMA), along with complex disease-inducing variations linked with Gaucher Disease (GD) and susceptibility to GBA1-related Parkinson’s Disease (PD), is impeccable. The integration of PCR (polymerase chain reaction)-free technology by CentoGenome in areas of the genome that are difficult to sequence will significantly reduce bias and provide high-quality sequence data. This information will offer deeper insights into coding, regulatory, and intronic regions.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

Which Regions Are Driving Growth in the Rare Disease Diagnostics Market?

North America was the largest region in the rare disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12651

This Report Delivers Insight On:

1. How big is the rare disease diagnostics market, and how is it changing globally?

2. Who are the major companies in the rare disease diagnostics market, and how are they performing?

3. What are the key opportunities and risks in the rare disease diagnostics market right now?

4. Which products or customer segments are growing the most in the rare disease diagnostics market?

5. What factors are helping or slowing down the growth of the rare disease diagnostics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model